Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluoxetine pharmacogenetics in child and adult populations.

European child & adolescent psychiatry - 1 Nov 2012

Blazquez Ana, Mas Sergi, Plana Ma Teresa, Lafuente Amàlia, Lázaro Luisa

Abstract excerpt

Although fluoxetine is useful in the treatment of major depression, 30-40 % of the patients do not respond to therapy. The response seems to be influenced by certain genes which are involved in the drug's pharmacodynamics and pharmacokinetics. The present study reviews the literature on genetic contributions to fluoxetine response in children and adults, and concludes that the different polymorphisms of CYP2D6...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Selective Serotonin Reuptake Inhibitors
Share to Depressive Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Fluoxetine

Share to Membrane Transport Proteins

Share to Pharmacogenetics

Share to Receptors, Serotonin

Share to Serotonin

Source

Identifiers

PMID: 22791347
DOI: 10.1007/s00787-012-0305-6

Genes

COMT
CRHR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluoxetine pharmacogenetics in child and adult populations.PMID 22791347Read ↗

Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.Semantic proximity Read ↗

Impact of Cytochrome P450 Genetic Variation on Patient-Reported Symptom Improvement and Side Effects Among Children and Adolescents Treated with Fluoxetine.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group Guideline for the Gene-Drug Interaction of CYP2D6 and COMT with Atomoxetine, Methylphenidate and ClonidineSemantic proximity Read ↗

Do we need pharmacogenetics to personalize antidepressant therapy?Semantic proximity Read ↗

Pharmacogenomics and antidepressant drugs.Semantic proximity Read ↗

Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism.Semantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidateSemantic proximity Read ↗

Pharmacogenetics. Promise and potential in child and adolescent psychiatry.Semantic proximity Read ↗

Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disordersSemantic proximity Read ↗

Pharmacogenetics of antidepressants: clinical aspects.Semantic proximity Read ↗

Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.Semantic proximity Read ↗

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.